Dr. Eric Levine’s cutting-edge autism research at UConn School of Medicine is reprogramming the donated skin or blood cells ...
WTIC Hartford on MSN2d
UConn’s Dr. Levine receives $400K for autism research from Philadelphia Eagles foundationThis is one of 22 cutting-edge projects selected to share in a total of $8.1 million in grants raised through the Eagles ...
Ionis has committed to a phase 3 programme for its antisense therapy for rare genetic disorder Angelman syndrome, just weeks after Biogen decided against exercising an option to license the drug.
Plans for new social care charges in East Renfrewshire have been given the go-ahead. The council approved the £20 per hour fees for non-residential care, which include social supports, day ...
Neuren Pharmaceuticals (ASX: NEU) has been granted the chance to talk to the U.S. Food and Drug Administration (FDA) about ...
Dr. Eric Levine’s cutting-edge autism research at UConn is reprogramming the donated skin or blood cells of Angelman or Dup15q syndrome patients to develop them in the lab into brain cells that ...
Pharmaceutical announced new data demonstrating treatment with UX111 AAV gene therapy led to a statistically significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback